Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable

Clinical Drug Investigation

Volumn 32, Issue 4, 2012, Pages 267-279

  Rosa, Fernanda ^a   Schreiner, Andreas ^b   Thomas, Pierre ^c   Sherif, Tarek ^d  

^a Casa de Saúde S Rafael ^*  (Portugal)

^b JANSSEN CILAG GMBH   (Germany)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d KING KHALID NATIONAL GUARD HOSPITAL   (Saudi Arabia)

Author keywords

Antipsychotics; Olanzapine; Risperidone; Schizoaffective disorder; Schizophrenia

Indexed keywords

OLANZAPINE; RISPERIDONE;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYNDROME; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOKINESIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PARKINSONISM; PRIORITY JOURNAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; TARDIVE DYSKINESIA; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; VITAL SIGN;

ADMINISTRATION, ORAL; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; INJECTIONS; MALE; MIDDLE AGED; PATIENT SATISFACTION; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RISPERIDONE; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84858041827     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11599080-000000000-00000     Document Type: Article

References (29)

1. Altamura AC, Armadoros D, Jaeger M, et al. Importance of open access to atypical antipsychotics for the treatment of schizophrenia and bipolar disorder: a European perspective. Curr Med Res Opin 2008; 24 (8): 2271-82
2. Buckley PF, Correll CU. Strategies for dosing and switching antipsychotics for optimal clinical management. J Clin Psychiatry 2008; 69 Suppl. 1: 4-17
3. Komossa K, Rummel-Kluge C, Hunger H, et al. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2010; (3): CD006654
4. Komossa K, Rummel-Kluge C, Hunger H, et al. Ziprasidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2009; (4): CD006627
5. Komossa K, Rummel-Kluge C, Schmid F, et al. Aripirprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2009; (4): CD006569
6. Komossa K, Rummel-Kluge C, Schmid F, et al. Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2010; (1): CD006625
7. Komossa K, Rummel-Kluge C, Schwarz S, et al. Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2011; (1): CD006626
8. Law MR, Soumerai SB, Ross-Degnan D, et al. A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia. J Clin Psychiatry 2008; 69 (1): 47-53 (Pubitemid 351281996)
9. Möller HJ, Llorca PM, Sacchetti E, et al. Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. Int Clin Psychopharmacol 2005; 20 (3): 121-30 (Pubitemid 40571509)
10. Olivares JM, Rodriguez-Morales A, Diels J, et al. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry 2009; 24 (5): 287-96
11. Davis JM, Leucht S. Commentary on strategies for switching antipsychotics. BMC Med 2008; 6: 18
12. Perez-Iglesias R, Crespo-Facorro B, Amado JA, et al. A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone. J Clin Psychiatry 2007; 68 (11): 1733-40 (Pubitemid 350247503)
13. Perez-Iglesias R, Crespo-Facorro B, Martinez-Garcia O, et al. Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naïve population. Schizophr Res 2008; 99 (1-3): 13-22 (Pubitemid 351255577)
14. Saddichha S, Manjunatha N, Ameen S, et al. Effect of olanzapine, risperidone, and haloperidol treatment on weight and body mass index in first-episode schizophrenia patients in India: a randomized, double-blind, controlled, prospective study. J Clin Psychiatry 2007; 68 (11): 1793-8 (Pubitemid 350247510)
15. Su KP, Wu PL, Pariante CM. A crossover study on lipid and weight changes associated with olanzapine and risperidone. Psychopharmacology (Berl) 2005; 183 (3): 383-6 (Pubitemid 41660425)
16. Garman PM, Ried LD, Bengtson MA, et al. Effect on lipid profiles of switching from olanzapine to another secondgeneration antipsychotic agent in veterans with schizophrenia. J Am Pharm Assoc 2007; 47 (3): 373-8
17. Meyer JM, Pandina G, Bossie CA, et al. Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study. Clin Ther 2005; 27 (12): 1930-41 (Pubitemid 43293215)
18. Ganguli R, Brar JS, Mahmoud R, et al. Assessment of strategies for switching patients from olanzapine to risperidone: a randomized, open-label, rater-blinded study. BMC Med 2008; 6: 17
19. American Psychiatric Association (APA). Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: APA, 1994
20. Guy W. Clinical Global Impressions. In: ECDEU Assessment Manual for Psychopharmacology; Rockville (MD): US Department of Health and Human Services, Public Health Service, Alcohol, Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research Branch, 1976: 218-22
21. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13 (2): 261-76 (Pubitemid 18039085)
22. Chouinard G, Ross-Chouinard A, Annable L, et al. Extrapyramidal Symptom Rating Scale. Can J Neurol Sci 1980; 7 (3): 233
23. Chouinard G, Margolese HC. Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr Res 2005; 76 (2-3): 247-65 (Pubitemid 40804771)
24. Welborn TA, Dhaliwal SS. Preferred clinical measures of central obesity for predicting mortality. Eur J Clin Nutr 2007; 61 (12): 1373-9 (Pubitemid 350245910)
25. Gastpar M, Masiak M, Latif MA, et al. Sustained improvement of clinical outcome with risperidone long-acting injectable in psychotic patients previously treated with olanzapine. J Psychopharmacol 2005; 19 (5 Suppl.): 32-8 (Pubitemid 41392295)
26. Gastpar M, Chrzanowski W, Latif MA, et al. Olanzapine to RLAI: improvements in psychotic patients [abstract]. Presented at the 8th World Congress of Biological Psychiatry (WCBP); 2005 Jun 28-Jul 3; Vienna
27. Csernansky JG, Mahmoud R, Brenner R, et al. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002; 346 (1): 16-22 (Pubitemid 34438915)
28. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 1997; 58 (12): 538-46 (Pubitemid 28100274)
29. Gharabawi GM, Gearhart NC, Lasser RA, et al. Maintenance therapy with once-monthly administration of longacting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing interval. Ann Gen Psychiatry 2007; 6: 3